Immunological probes in cardiovascular disease
Sir, Dr Haber's recent paper (Br HeartJr 1982; 47: 1-10) describes the use of Fab (digoxin-specific Fab fragments of sheep IgG/Wellcome) in the treatment of digoxin toxicity. We have used the drug in 13 patients who we felt would benefit from the rapid reversal ofthe effects of digoxin. Clinical and electrocardiographic improvement occurred within four hours in all toxic patients treated, with the'exception of a neonate who was asystolic for 10 minutes before Fab was given. There were no overt immunological or haemodynamic side effects.
We feel that attention shcould be drawn to the results (Table) obtained with various radioimmunoassays Sir, The question raised by Jennings and his colleagues is a difficult one to resolve. None of the methods that they have used to determine free digoxin concentration is entirely reliable. As they correctly point out, assay methods based on an immobilised antibody yield false results because all the labelled digoxin is bound to excess Fab from the patient's plasma. Any assay method based on precipitation of antibody will give uncertain results, because the conditions for precipitation of Fab and antibody differ and are dependent on the method chosen. The charcoal method for absorbing free digoxin is likely to be more reliable, but only if the affinity of the Fab used in therapy is similar or higher than the affinity ofthe assay antibody. Ifthe Fab is of significantly lower affinity, then there, will be transfer of labelled digoxin from Fab to charcoal, resulting in falsely raised free digoxin concentrations. 1 2 The only entirely reliable method is equilibrium dialysis, though this is admittedly tedious, time consuming, and not really applicable to the routine clinical laboratory.
